The assessment of tumor PD-L1 expression by immunohistochemistry (IHC) predicts the efficacy of pembrolizumab in metastatic TNBC, while patients with higher levels of stromal tumor-infiltrating lymphocyte levels or PD-L1 expression derive benefit from nivolumab in early-stage HR + BC [1,3]. The gene discussed is CD274; the disease is breast cancer.